Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Non-Current Assets (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Non-Current Assets for 7 consecutive years, with -$2.0 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets changed N/A year-over-year to -$2.0 billion, compared with a TTM value of -$1.9 billion through Sep 2025, changed N/A, and an annual FY2024 reading of $21.6 million, up 25.26% over the prior year.
  • Non-Current Assets was -$2.0 billion for Q3 2025 at Avidity Biosciences, down from $21.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $21.6 million in Q4 2024 and bottomed at -$2.0 billion in Q3 2025.
  • Average Non-Current Assets over 5 years is -$109.3 million, with a median of $16.4 million recorded in 2021.
  • The sharpest move saw Non-Current Assets skyrocketed 640.5% in 2021, then decreased 3.53% in 2022.
  • Year by year, Non-Current Assets stood at $16.4 million in 2021, then decreased by 3.53% to $15.9 million in 2022, then grew by 8.77% to $17.2 million in 2023, then increased by 25.26% to $21.6 million in 2024, then crashed by 9199.82% to -$2.0 billion in 2025.
  • Business Quant data shows Non-Current Assets for RNA at -$2.0 billion in Q3 2025, $21.6 million in Q4 2024, and $18.6 million in Q2 2024.